» Articles » PMID: 33534626

Trends in Classifying Vaccine Hesitancy Reasons Reported in the WHO/UNICEF Joint Reporting Form, 2014-2017: Use and Comparability of the Vaccine Hesitancy Matrix

Overview
Date 2021 Feb 3
PMID 33534626
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Since 2014, the World Health Organization (WHO) member states have been annually reporting vaccine hesitancy reasons, using the WHO/UNICEF Joint Reporting Form (JRF). The Vaccine Hesitancy Matrix (VHM), developed by a WHO strategic advisory group of experts, can serve as an important tool to categorize vaccine hesitancy reasons reported in the JRF. We aimed to describe the reasons for vaccine hesitancy reported globally from 2014 to 2017 to ascertain trends over time and understand the comparability of using the VHM to classify hesitancy reasons from 2014 to 2016 based on previously published literature. We conducted a quantitative content analysis to code and categorize vaccine hesitancy reasons reported in the JRF from 2014 to 2017. Vaccine hesitancy trends were consistent from 2014 to 2017, where vaccine hesitancy reasons were mainly related to "individual and group level influences" (59%) followed by "contextual influences" (25%), and "vaccine- or vaccination-specific issues" (16%). Comparability of our approach to categorize vaccine hesitancy to the previously published JRF data showed that results were mostly but not entirely consistent. Major differences in categorizing vaccine hesitancy were noted between two specific reasons - "experience with past vaccination" (under "individual and group influences") and "risk/benefit- scientific evidence" (under "vaccine and vaccination-specific issues"); this was usually due to lack of clear definitions in some sub-categories and generic responses reported in the JRF. The JRF hesitancy module may benefit from modifications to improve the data quality. Understanding global vaccine hesitancy is crucial and JRF can serve as an important tool, especially with the potential introduction of a COVID-19 vaccine.

Citing Articles

Factors Influencing COVID-19 Vaccination among Primary Healthcare Nurses in the Pandemic and Post-Pandemic Period: Cross-Sectional Study.

Pristov Z, Lobe B, Socan M Vaccines (Basel). 2024; 12(6).

PMID: 38932331 PMC: 11209193. DOI: 10.3390/vaccines12060602.


Exploring human papillomavirus vaccine hesitancy among college students and the potential of virtual reality technology to increase vaccine acceptance: a mixed-methods study.

Yoon S, Kim H, An J, Jin S Front Public Health. 2024; 12:1331379.

PMID: 38414894 PMC: 10896851. DOI: 10.3389/fpubh.2024.1331379.


Primary Care and Community-Based Partnerships to Enhance HPV Vaccine Delivery.

Carney P, Engstrom M, Barnes C, Ramalingam N, Dickinson C, Cox C J Prim Care Community Health. 2024; 15():21501319241231405.

PMID: 38411101 PMC: 10901053. DOI: 10.1177/21501319241231405.


Group-based trajectory models of integrated vaccine delivery and equity in low- and middle-income countries.

Ravi S, Vecino-Ortiz A, Potter C, Merritt M, Patenaude B Int J Equity Health. 2024; 23(1):5.

PMID: 38195588 PMC: 10775446. DOI: 10.1186/s12939-023-02088-x.


A Qualitative Analysis of Social-Ecological Factors Shaping Childhood Immunisation Hesitancy and Delay in the Eastern Province of Saudi Arabia.

Alabadi M, Pitt V, Aldawood Z Vaccines (Basel). 2023; 11(9).

PMID: 37766077 PMC: 10536341. DOI: 10.3390/vaccines11091400.


References
1.
Dube E, Gagnon D, Nickels E, Jeram S, Schuster M . Mapping vaccine hesitancy--country-specific characteristics of a global phenomenon. Vaccine. 2014; 32(49):6649-54. PMC: 5355208. DOI: 10.1016/j.vaccine.2014.09.039. View

2.
Eskola J, Duclos P, Schuster M, MacDonald N . How to deal with vaccine hesitancy?. Vaccine. 2015; 33(34):4215-7. DOI: 10.1016/j.vaccine.2015.04.043. View

3.
Stahl J, Cohen R, Denis F, Gaudelus J, Martinot A, Lery T . The impact of the web and social networks on vaccination. New challenges and opportunities offered to fight against vaccine hesitancy. Med Mal Infect. 2016; 46(3):117-22. DOI: 10.1016/j.medmal.2016.02.002. View

4.
MacDonald N . Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33(34):4161-4. DOI: 10.1016/j.vaccine.2015.04.036. View

5.
Marti M, de Cola M, MacDonald N, Dumolard L, Duclos P . Assessments of global drivers of vaccine hesitancy in 2014-Looking beyond safety concerns. PLoS One. 2017; 12(3):e0172310. PMC: 5332020. DOI: 10.1371/journal.pone.0172310. View